Scarica l'app Stockscreener
218.19
0.06%
0.21
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$218.40
Aprire:
$219.34
Volume 24 ore:
273.29K
Relative Volume:
0.19
Capitalizzazione di mercato:
$31.66B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
21.03
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
+12.14%
1M Prestazione:
+11.48%
6M Prestazione:
-11.95%
1 anno Prestazione:
-14.77%
Intervallo 1D:
$216.52
$219.98
Intervallo di 1 settimana:
$196.99
$222.43
Portata 52W:
$180.26
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, MDLN, ALC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
218.28 | 30.41B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
429.38 | 150.88B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
157.50 | 43.56B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.96 | 36.52B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.44 | 33.97B | 10.63B | 819.00M | 1.59B | 1.6577 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Form 144 RESMED INC For: 7 July By Investing.com - Investing.com Canada
Michael Farrell to sell 4,991 RMD shares (NYSE: RMD) - Stock Titan
ResMed stock trades on Nasdaq. Focus stays on sleep apnea demand. - AD HOC NEWS
Why Resmed (RMD) Stock Is Up Today - Moomoo
ResMed Inc (RMD) Shares Surge 4.2% -- What GF Score of 90 Tells Investors - GuruFocus
ResMed Inc. stock rises Monday, outperforms market - MarketWatch
RMDResmed Inc Options - Finviz
ResMed Inc. (RMD) Stock Analysis: A 24% Upside Potential With Robust Revenue Growth - DirectorsTalk Interviews
Precision Trading with Resmed Inc. (RMD) Risk Zones - Stock Traders Daily
Ord Minnett Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD) - The Globe and Mail
ResMed (RMD) Is Up 5.6% After Russell Growth Index Removal Amid Brighter Analyst Outlook - Sahm
Why ResMed (RMD) Stock Is Trading Up Today - Yahoo Finance
ResMed Inc. stock rises Thursday, outperforms market - MarketWatch
ResMed (RMD) Added to Goldman Sachs' APAC Conviction List - GuruFocus
Is It Too Late to Buy ResMed Inc (RMD) After 3.2% Rally? GF Value Says Undervalued - GuruFocus
ResMed Inc. stock rises Wednesday, outperforms market - MarketWatch
ResMed (RMD) Upgraded to Buy: Here's Why - Yahoo Finance UK
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet - Yahoo! Finance Canada
ResMed (NYSE: RMD) reports 1.95% stake in Nyxoah — 1.94M shares - Stock Titan
ResMed (RMD) Stock Looks Cheap Even As The Market Stays Cautious - Yahoo Finance
Resmed to report Q4FY26 earnings on August 6, 2026 - scanx.trade
Should ResMed’s Russell Growth Index Exit and Volatility Spike Require Action From ResMed (RMD) Investors? - Yahoo Finance
ResMed Gets PTAB To Ax 1 Out Of 2 Sleep Apnea Patents - Law360
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026 - The Manila Times
ResMed Inc options activity points to a potential volatility spike. Consensus earnings expectations - AD HOC NEWS
ResMed leads sleep apnea market with strong growth and margin improvements, rated Buy with 12% safety margin. - Pluang
ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point - Seeking Alpha
ResMed Inc.(NYSE: RMD) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Are Options Traders Betting on a Big Move in ResMed Stock? - TradingView
ResMed adjusts index footprint, shares hold gains on NYSE and ASX - AD HOC NEWS
ResMed Inc.(NYSE: RMD) dropped from Russell 3000E Growth Benchmark - marketscreener.com
ResMed Inc.(NYSE: RMD) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Daily Brief Australia: Cochlear Ltd, Commonwealth Bank of Australia, Fortescue Metals, ResMed Inc and more - Smartkarma
ResMed Inc.(NYSE: RMD) dropped from Russell 3000 Growth Benchmark - marketscreener.com
AirSense 10 ClimateLineAir Heated Tube from ResMed Inc.quieter nights with smarter humidity - Ad-hoc-news.de
ResMed muted ahead of next earnings, shares trade steadily on NYSE - Ad-hoc-news.de
Enterprise value to EBIT forward of ResMed Inc. – NYSE:RMD - TradingView
OLD National Bancorp IN Has $4.58 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. sees fresh institutional buying, shares hover near 200 dollars - Ad-hoc-news.de
ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh - TradingView
Price to earnings forward of ResMed Inc. – NYSE:RMD - TradingView
Price to earnings forward of ResMed Inc. CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh – MUN:RMEA - TradingView
Price to sales forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed clears key trading range, shares hold firm between support and resistance - Ad-hoc-news.de
Enterprise value to revenue forward of ResMed Inc. – NYSE:RMD - TradingView
Should you continue to hold Resmed stock in your portfolio? - MSN
ResMed clears a fresh 52-week high, shares extend their Nasdaq run - Ad-hoc-news.de
Why ResMed Inc (RMD) Is Set to Outperform the Market: Insights i - GuruFocus
Price to book forward of ResMed Inc. – NYSE:RMD - TradingView
ResMed Stock is Down 20% in 2026. Is It a Buying Opportunity or a Warning Sign? - TIKR.com
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Resmed Inc Azioni (RMD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO |
Jun 08 '26 |
Sale |
193.96 |
4,991 |
968,064 |
466,256 |
1.32%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):